Výsledky vyhledávání - "D. A. Vorobiof"

First line therapy with paclitaxel (Taxol®) and pegylated liposomal doxorubicin (Caelyx®) in patients with metastatic breast cancer: a multicentre phase II study

Autor: C. Slabber, D. A. Vorobiof, Martin Chasen, C. Mohammed, Bernardo Leon Rapoport, G. McMichael, R. Eek

Publikováno v: The Breast. 13:219-226

The aim of this multicentric phase II study was to investigate the efficacy and toxicity of a combination of chemotherapy containing paclitaxel (Taxol) and a novel compound, a liposomal encapsulated doxorubicin (Caelyx), as first line therapy for pat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13cddeaa3d7902d8fde35cf9dabd6cb7
https://doi.org/10.1016/j.breast.2004.01.006

Zobrazit plný text záznamu

Phase II clinical trial of carboplatin and docetaxel in patients with metastatic ovarian cancer: Active combination with low incidence of peripheral neuropathy

Autor: Martin Chasen, Bernardo Leon Rapoport, R. Mahomed, G. L. Cohen, M. Karime, D. A. Vorobiof

Publikováno v: International Journal of Gynecological Cancer. 13:287-291

During the past 2 decades there have been chemotherapeutic advances in the management of patients with advanced epithelial ovarian cancer. Nevertheless, new drug combinations aimed at increasing response and survival and decreasing toxicities are und

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da9cabc76c5af88a11f3ab29787ff187
https://doi.org/10.1046/j.1525-1438.2003.13203.x

Zobrazit plný text záznamu

Phase II trial of gemcitabine and vinorelbine in patients with stage III B and IV non small cell lung cancer

Autor: Martin Chasen, D. A. Vorobiof

Publikováno v: Revista de Oncología. 5:21-26

Background. Gemcitabine and vinorelbine are active agents in advanced non-small cell lung cancer. We conducted a phase II trial of this combination in untreated patients with stage III B or IV non-small cell lung cancer.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ed3c10b8a90b0d247972ab3537c7979b
https://doi.org/10.1007/bf02712837

Zobrazit plný text záznamu

Malignant pleural mesothelioma: a phase II trial with docetaxel

Autor: L. Fourie, D. A. Vorobiof, N. Cronje, G. McMichael, Bernardo Leon Rapoport, Martin Chasen, D. Hacking, Raymond P. Abratt

Publikováno v: Annals of Oncology. 13:412-415

Current cytotoxic therapy has been of limited benefit to patients with malignant pleural mesothelioma. Single agent chemotherapy has been extensively evaluated in small series of phase II clinical trials, with disappointing responses. Docetaxel, an e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64b551230df0048f54aaa69161dc81fa
https://doi.org/10.1093/annonc/mdf046

Zobrazit plný text záznamu

Phase II study of pegylated liposomal doxorubicin and carboplatin in patients with platinum-sensitive and partially platinum-sensitive metastatic ovarian cancer

Autor: Bernardo Leon Rapoport, H. S. Hlophe, C. Slabber, A. S. Alberts, D. A. Vorobiof, C. Mohammed

Publikováno v: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 19(6)

Objective:This phase II study assessed the activity and safety of pegylated liposomal doxorubicin (PLD) plus carboplatin in relapsed ovarian cancer (ROC).Method:Forty women with platinum-sensitive and partially platinum-sensitive ROC were treated wit

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a5cf36f7e6330746f03c35d2ac9f5e
https://pubmed.ncbi.nlm.nih.gov/19820382

Zobrazit plný text záznamu

Breast cancer incidence in South Africa

Autor: D A, Vorobiof, F, Sitas, G, Vorobiof

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 19

Cancer in South Africa is an emerging health problem, with breast cancer being one of the leading cancers in women, following similar worldwide statistics. Lifetime risks of developing breast cancer vary from a low of one in 81 in African women (simi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8c2ad5b36c353e1c7127fca2b76401ac
https://pubmed.ncbi.nlm.nih.gov/11560987

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání